Cover Image
市場調查報告書

美國的癌症相關的MR及核/分子醫學影像系統診斷市場

U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems

出版商 Medtech Insight 商品編碼 316328
出版日期 內容資訊 英文 180 pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的癌症相關的MR及核/分子醫學影像系統診斷市場 U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems
出版日期: 2014年10月01日 內容資訊: 英文 180 pages
簡介

2014年美國推算約170萬人診斷出癌症,約58萬5,720人死於癌症。雖然癌症治療進步,癌症在該國仍為次於心臟疾病的第二大死因。現在,為了與癌症作戰,採用包含核磁共振攝影和NMMI(核/分子醫學影像)等診斷用呈像的各種方式,使醫生幾乎可在可治療階段偵測到惡性腫瘤。在2013年中,美國癌症相關核磁共振攝影、NMMI治療約實施1,510萬件。同時,這些治療產生約5億9,890萬美元的系統銷售額。這些癌症相關適應症用診斷系統的銷售額,在預測期間內預計以年複合成長率5.5%增加,2017年達到7億8,010萬美元。

本報告提供美國的新癌症案例,包含得病率及癌症死亡等的統計資料,為您概述為以下內容。

摘要整理

第1章 癌症統計的更新

  • 癌症細胞的採集能力
  • 包含癌症進程的基因變化的目錄
  • 癌症進程相關的風險因素
  • 癌症的分期
  • 新的癌症案例,癌症的得病率,及癌症的死亡
  • 主要的癌症類型臨床、統計資料
    • 腦、其他神經系統癌症
    • 乳癌
    • 大腸癌
    • 腎臟/腎盂癌
    • 白血病
    • 肺/支氣管癌
    • 淋巴瘤
    • 黑色素瘤
    • 口腔/咽喉癌
    • 卵巢癌
    • 胰臟癌
    • 前列腺癌
    • 甲狀腺癌
    • 膀胱癌
    • 子宮癌

第2章 美國的癌症相關MRI及NMMI(核/分子醫學影像)系統診斷市場

  • 核磁共振攝影系統:市場分析
  • NMMI(核/分子醫學影像)系統:市場分析

第3章 企業簡介

  • Digirad Corporation
  • Esaote North America, Inc./Esaote SPA
  • GE Healthcare, Inc./General Electric Company
  • Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
  • ntraMedical Imaging LLC
  • NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co LTD/Samsung Group
  • Neusoft Medical Systems Co LTD/Neusoft Corporation
  • Philips Healthcare, Inc./Royal Philips NV
  • Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • Toshiba America Medical Systems, Inc./Toshiba Corporation
目錄
Product Code: A416

It is estimated that nearly 1.7 million people in the United States (U.S.) will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. Despite advancements in oncology (the branch of medicine that deals with cancer), the disease remains the second-leading cause of death in the country after heart disease. Today, a constellation of methods are used in the fight against cancer, including diagnostic imaging modalities such as magnetic resonance imaging (MRI) and nuclear/molecular medicine imaging (NMMI), which allow physicians to detect malignancies at their most treatable stages.

In the U.S., approximately 15.1 million diagnostic oncology-related MRI and NMMI procedures were performed in 2013. Together, these procedures generated approximately $595.9 million in corresponding systems sales; it is expected that during the forecast period covered by this report, sales of these systems for diagnostic oncology-related indications will increase at a compound annual rate of 5.5%, reaching an estimated $780.1 million in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.

Covered topics in this report include a statistical overview of cancer in the U.S. including cancer incidence and prevalence, cancer-related deaths, and cancer risk factors; MRI applications and indications; MRI computer-aided detection; MRI systems including bore-less, enclosed, flared-gantry, intraoperative, open, and wide-bore models; NMMI applications and indications; positron emission tomography (PET) and hybrid PET systems; radioisotope/radiopharmaceutical shortages; single-photon emission computed tomography (SPECT) and hybrid SPECT systems, total and diagnostic oncology-related MRI and NMI procedures volumes and market forecasts, among others.

Table of Contents

EXECUTIVE SUMMARY

  • i. Cancer Overview
  • ii. Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Systems Market
    • a. Magnetic Resonance Imaging Market Segment
    • b. Nuclear/Molecular Medicine Imaging Systems Market Segment
  • iv. Methodology
  • Exhibit ES-1: Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer
  • Exhibit ES-2: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit ES-3: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit ES-4: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit ES-5: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit ES-6: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
  • Exhibit ES-6: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018

1. CANCER STATISTICS UPDATE

  • 1.1. Acquired Capabilities of Cancer Cells
  • 1.2. Cataloging Genomic Alterations Involved in the Development of Cancer
  • 1.3. Risk Factors Associated with the Development of Cancer
  • 1.4. Cancer Staging
  • 1.5. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • 1.6. Clinical and Statistical Data for Selected Types of Cancer
    • 1.6.1. Brain and Other Nervous System Cancers
      • 1.6.1.1. Etiology
      • 1.6.1.2. Epidemiology
    • 1.6.2. Breast Cancer
      • 1.6.2.1. Etiology
      • 1.6.2.2. Epidemiology
    • 1.6.3. Colorectal Cancer
      • 1.6.3.1. Etiology
      • 1.6.3.2. Epidemiology
    • 1.6.4. Kidney/Renal Pelvis Cancer
      • 1.6.4.1. Etiology
      • 1.6.4.2. Epidemiology
    • 1.6.5. Leukemia
      • 1.6.5.1. Etiology
      • 1.6.5.2. Epidemiology
    • 1.6.6. Lung/Bronchus Cancer
      • 1.6.6.1. Etiology
      • 1.6.6.2. Epidemiology
    • 1.6.7. Lymphoma
      • 1.6.7.1. Etiology
      • 1.6.7.2. Epidemiology
    • 1.6.8. Melanoma
      • 1.6.8.1. Etiology
      • 1.6.8.2. Epidemiology
    • 1.6.9. Oral Cavity and Pharyngeal Cancers
      • 1.6.9.1. Etiology
      • 1.6.9.2. Epidemiology
    • 1.6.10. Ovarian Cancer
      • 1.6.10.1. Etiology
      • 1.6.10.2. Epidemiology
    • 1.6.11. Pancreatic Cancer
      • 1.6.11.1. Etiology
      • 1.6.11.2. Epidemiology
    • 1.6.12. Prostate Cancer
      • 1.6.12.1. Etiology
      • 1.6.12.2. Epidemiology
    • 1.6.13. Thyroid Cancer
      • 1.6.13.1. Etiology
      • 1.6.13.2. Epidemiology
    • 1.6.14. Urinary Bladder Cancer
      • 1.6.14.1. Etiology
      • 1.6.14.2. Epidemiology
    • 1.6.15. Uterine Cancer
      • 1.6.15.1. Etiology
      • 1.6.15.2. Epidemiology
  • Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer
  • Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures
  • Exhibit 1-3: Breast Cancer, Facts And Figures
  • Exhibit 1-4: Colorectal Cancer, Facts And Figures
  • Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures
  • Exhibit 1-6: Leukemia, Facts and Figures
  • Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures
  • Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-10: Melanoma of the Skin, Facts and Figures
  • Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures
  • Exhibit 1-12: Ovarian Cancer, Facts and Figures
  • Exhibit 1-13: Pancreatic Cancer, Fact and Figures
  • Exhibit 1-14: Prostate Cancer, Facts And Figures
  • Exhibit 1-15: Thyroid Cancer, Fact and Figures
  • Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures
  • Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures
  • Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures

2. U.S. MARKETS FOR DIAGNOSTIC ONCOLOGY-RELATED MAGNETIC RESONANCE AND NUCLEAR/MOLECULAR MEDICINE IMAGING SYSTEMS

  • 2.1. Magnetic Resonance Imaging Systems, Market Analysis
    • 2.1.1. Technologies
    • 2.1.2. Procedure Volumes
    • 2.1.3. Products
    • 2.1.4. Market Forecast
    • 2.1.5. Competitive Analysis
  • 2.2. Nuclear/Molecular Medicine Imaging Systems, Market Analysis
    • 2.2.1. Technologies
      • 2.2.1.1. Imaging with Positron Emission Tomography Scanners
      • 2.2.1.2. Imaging with Gamma Cameras
      • 2.2.1.3. Imaging with Hybrid Devices
    • 2.2.2. Procedure Volumes
    • 2.2.3. Products
    • 2.2.4. Market Forecast
    • 2.2.5. Competitive Analysis
  • Exhibit 2-1: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-2: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-3: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit 2-4: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit 2-5: Magnetic Resonance Imaging, Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-6: 2014, Selected Magnetic Resonance Imaging Systems
  • Exhibit 2-7: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
  • Exhibit 2-8: 2013, Magnetic Resonance Imaging Systems Market, Share by Supplier
  • Exhibit 2-9: Nuclear/Molecular Medicine Imaging, Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-10: 2014, Selected Nuclear/Molecular Medicine Imaging Systems
  • Exhibit 2-11: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018
  • Exhibit 2-12: 2013, Nuclear/Molecular Medicine Systems Market, Share by Supplier

3. COMPANY PROFILES

  • 3.1. Digirad Corporation
  • 3.2. Esaote North America, Inc./Esaote SPA
  • 3.3. GE Healthcare, Inc./General Electric Company
  • 3.4. Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
  • 3.5. IntraMedical Imaging LLC
  • 3.6. NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co LTD/Samsung Group
  • 3.7. Neusoft Medical Systems Co LTD/Neusoft Corporation
  • 3.8. Philips Healthcare, Inc./Royal Philips NV
  • 3.9. Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • 3.10. Toshiba America Medical Systems, Inc./Toshiba Corporation

APPENDIX: COMPANY LISTING

Back to Top